Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer

Overview

Journal ACS Med Chem Lett

Publisher American Chemical Society

Specialty Chemistry

Date 2019 Apr 19

PMID 30996813

Citations 29

Authors

Tiziano Marzo

Lara Massai

Alessandro Pratesi

Matteo Stefanini

Damiano Cirri

Francesca Magherini

Matteo Becatti

Ida Landini

Stefania Nobili

Enrico Mini

Olivia Crociani

Annarosa Arcangeli

Serena Pillozzi

Tania Gamberi

Luigi Messori

Affiliations

Soon will be listed here.

Abstract

In recent years, a few successful attempts were made to repurpose the clinically approved antiarthritic gold drug, Auranofin (), as an anticancer agent. The present study shows that the iodido(triethylphosphine)gold(I) complex, ( hereafter)-an analogue where the thiosugar ligand is simply replaced by one iodide ligand-manifests a solution chemistry resembling that of and exerts similar cytotoxic and proapoptotic effects on A2780 human ovarian cancer cells . However, when evaluated in a preclinical orthotopic model of ovarian cancer, produces a far superior anticancer action than inducing a nearly complete tumor remission. The highly promising performances here documented for warrant its further evaluation as a drug candidate for ovarian cancer treatment.

Citing Articles

A clinical prognostic model of oxidative stress-related genes linked to tumor immune cell infiltration and the prognosis of ovarian cancer patients.

Li L, Zhang W, Sun Y, Zhang W, Lu M, Wang J Heliyon. 2024; 10(7):e28442.

PMID: 38560253 PMC: 10981114. DOI: 10.1016/j.heliyon.2024.e28442.

Development of immunoliposomes containing cytotoxic gold payloads against HER2-positive breast cancers.

Ahad A, Aftab F, Michel A, Lewis J, Contel M RSC Med Chem. 2024; 15(1):139-150.

PMID: 38283233 PMC: 10809422. DOI: 10.1039/d3md00334e.

Shifting the Antibody-Drug Conjugate Paradigm: A Trastuzumab-Gold-Based Conjugate Demonstrates High Efficacy against Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Mouse Model.

Ahad A, Saeed H, Del Solar V, Lopez-Hernandez J, Michel A, Mathew J ACS Pharmacol Transl Sci. 2023; 6(12):1972-1986.

PMID: 38093840 PMC: 10714425. DOI: 10.1021/acsptsci.3c00270.

Auranofin Induces Lethality Driven by Reactive Oxygen Species in High-Grade Serous Ovarian Cancer Cells.

Abdalbari F, Martinez-Jaramillo E, Forgie B, Tran E, Zorychta E, Goyeneche A Cancers (Basel). 2023; 15(21).

PMID: 37958311 PMC: 10650616. DOI: 10.3390/cancers15215136.

Synthesis, Characterization, and Anticancer Activity of Phosphanegold(i) Complexes of 3-Thiosemicarbano-butan-2-one Oxime.

Zarewa S, Binobaid L, Sulaiman A, As Sobeai H, Alotaibi M, Alhoshani A Biomedicines. 2023; 11(9).

PMID: 37760953 PMC: 10525815. DOI: 10.3390/biomedicines11092512.

References

Shaw Iii C . Gold-based therapeutic agents. Chem Rev. 2001; 99(9):2589-600. DOI: 10.1021/cr980431o. View

Simon T, Kunishima D, Vibert G, Lorber A . Cellular antiproliferative action exerted by auranofin. J Rheumatol Suppl. 1979; 5:91-7. View

Crociani O, Zanieri F, Pillozzi S, Lastraioli E, Stefanini M, Fiore A . hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer. Sci Rep. 2013; 3():3308. PMC: 3839040. DOI: 10.1038/srep03308. View

Pratesi A, Gabbiani C, Michelucci E, Ginanneschi M, Papini A, Rubbiani R . Insights on the mechanism of thioredoxin reductase inhibition by gold N-heterocyclic carbene compounds using the synthetic linear selenocysteine containing C-terminal peptide hTrxR(488-499): an ESI-MS investigation. J Inorg Biochem. 2014; 136:161-9. DOI: 10.1016/j.jinorgbio.2014.01.009. View

Cassetta M, Marzo T, Fallani S, Novelli A, Messori L . Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections. Biometals. 2014; 27(4):787-91. DOI: 10.1007/s10534-014-9743-6. View

Micale N, Schirmeister T, Ettari R, Cinellu M, Maiore L, Serratrice M . Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities. J Inorg Biochem. 2014; 141:79-82. DOI: 10.1016/j.jinorgbio.2014.08.001. View

Roh J, Jang H, Kim E, Shin D . Targeting of the Glutathione, Thioredoxin, and Nrf2 Antioxidant Systems in Head and Neck Cancer. Antioxid Redox Signal. 2016; 27(2):106-114. DOI: 10.1089/ars.2016.6841. View

Capparelli E, Bricker-Ford R, Rogers M, McKerrow J, Reed S . Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent. Antimicrob Agents Chemother. 2016; 61(1). PMC: 5192119. DOI: 10.1128/AAC.01947-16. View

Marzo T, Cirri D, Gabbiani C, Gamberi T, Magherini F, Pratesi A . Auranofin, EtPAuCl, and EtPAuI Are Highly Cytotoxic on Colorectal Cancer Cells: A Chemical and Biological Study. ACS Med Chem Lett. 2017; 8(10):997-1001. PMC: 5641946. DOI: 10.1021/acsmedchemlett.7b00162. View

10.

Hou G, Liu P, Zhang S, Yang M, Liao J, Yang J . Elimination of stem-like cancer cell side-population by auranofin through modulation of ROS and glycolysis. Cell Death Dis. 2018; 9(2):89. PMC: 5833411. DOI: 10.1038/s41419-017-0159-4. View

11.

Scalcon V, Bindoli A, Rigobello M . Significance of the mitochondrial thioredoxin reductase in cancer cells: An update on role, targets and inhibitors. Free Radic Biol Med. 2018; 127:62-79. DOI: 10.1016/j.freeradbiomed.2018.03.043. View

12.

Magherini F, Fiaschi T, Valocchia E, Becatti M, Pratesi A, Marzo T . Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: a comparative proteomic study. Oncotarget. 2018; 9(46):28042-28068. PMC: 6021324. DOI: 10.18632/oncotarget.25556. View

13.

Marzo T, Cirri D, Pollini S, Prato M, Fallani S, Cassetta M . Auranofin and its Analogues Show Potent Antimicrobial Activity against Multidrug-Resistant Pathogens: Structure-Activity Relationships. ChemMedChem. 2018; 13(22):2448-2454. DOI: 10.1002/cmdc.201800498. View

14.

Mirabelli C, Johnson R, Hill D, Faucette L, Girard G, Kuo G . Correlation of the in vitro cytotoxic and in vivo antitumor activities of gold(I) coordination complexes. J Med Chem. 1986; 29(2):218-23. DOI: 10.1021/jm00152a009. View

15.

Bombardier C, Ware J, Russell I, Larson M, Chalmers A, Read J . Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial. Am J Med. 1986; 81(4):565-78. DOI: 10.1016/0002-9343(86)90539-5. View

16.

Mirabelli C, Johnson R, Sung C, Faucette L, Muirhead K, Crooke S . Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res. 1985; 45(1):32-9. View

17.

Sutton B, McGusty E, Walz D, Dimartino M . Oral gold. Antiarthritic properties of alkylphosphinegold coordination complexes. J Med Chem. 1972; 15(11):1095-8. DOI: 10.1021/jm00281a001. View